The primary goals of antiplatelet therapy in peripheral artery disease are the prevention of cardiovascular ischaemic events and maintenance of revascularization patency. Vorapaxar is a novel agent that has a demonstrated clinical benefit in a broad population of patients, and also decreases the progression of limb ischaemia.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
Drugs in R&D Open Access 06 January 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Criqui, M. H. et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 326, 381–386 (1992).
Rooke, T. W. et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124, 2020–2045 (2011).
Bonaca, M. P. et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 127, 1522–1529 (2013).
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002).
Baigent, C. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).
Berger, J. S., Krantz, M. J., Kittelson, J. M. & Hiatt, W. R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301, 1909–1919 (2009).
Wong, P. F., Chong, L. Y., Mikhailidis, D. P., Robless, P. & Stansby, G. Antiplatelet agents for intermittent claudication. Cochrane Database of Systematic Reviews Issue 11. Art. No.: CD001272. http://dx.doi.org/10.1002/14651858.CD001272.pub2.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308, 159–168 (1994).
Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has received research support from AstraZeneca.
Rights and permissions
About this article
Cite this article
Hiatt, W. Vorapaxar prevents progression of peripheral artery disease. Nat Rev Cardiol 10, 367–368 (2013). https://doi.org/10.1038/nrcardio.2013.66
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2013.66
